Mokari Atabak, CFO, reported a transaction classified as grant at CORCEPT THERAPEUTICS INC involving 138.000000 shares for an estimated $0.00. Reported holdings after the transaction were 16406.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to th…
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
The closing price on September 1, 2026 was used to calculate the withholding obligation.
Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the…
0 other filings
0 recent txs